Search research articles
Contact Us
Filters
Showing results (31-40 of 60) with videos related to
Page
of 6
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
October 15, 2021
Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington's disease
Daniele Bertoglio, Jeroen Verhaeghe, Alan Miranda, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
December 18, 2025
Preclinical evaluation of [<sup>11</sup>C]CHDI-009R for quantification of mutant huntingtin aggregates
Franziska Zajicek, Liesbeth Everix, Annemie Van Eetveldt, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
July 17, 2019
Validation and noninvasive kinetic modeling of [<sup>11</sup>C]UCB-J PET imaging in mice
Daniele Bertoglio, Jeroen Verhaeghe, Alan Miranda, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 24, 2022
Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [<sup>11</sup>C]CHDI-00485180-R and [<sup>11</sup>C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin
Aline Delva, Michel Koole, Kim Serdons, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 17, 2025
PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington's disease
Aline Delva, Michel Koole, Kim Serdons, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 13, 2020
The development of a structurally distinct series of BACE1 inhibitors via the (Z)-fluoro-olefin amide bioisosteric replacement
Michael Frohn, Longbin Liu, Aaron C Siegmund, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 17, 2023
In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease
Daniele Bertoglio, Alison R Weiss, William Liguore, et al.
Bioorganic & Medicinal Chemistry
|
April 18, 2016
Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling
Longbin Liu, Matthew R Lee, Joseph L Kim, et al.
Journal of Medicinal Chemistry
|
February 11, 2012
Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series
Longbin Liu, Mark H Norman, Matthew Lee, et al.
Journal of Medicinal Chemistry
|
April 28, 2015
Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis
Nuria A Tamayo, Mark H Norman, Michael D Bartberger, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 60) with videos related to
Sort By:
Page
of 6
European Journal of Nuclear Medicine and Molecular Imaging
|
October 15, 2021
Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington's disease
Daniele Bertoglio, Jeroen Verhaeghe, Alan Miranda, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
December 18, 2025
Preclinical evaluation of [<sup>11</sup>C]CHDI-009R for quantification of mutant huntingtin aggregates
Franziska Zajicek, Liesbeth Everix, Annemie Van Eetveldt, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
July 17, 2019
Validation and noninvasive kinetic modeling of [<sup>11</sup>C]UCB-J PET imaging in mice
Daniele Bertoglio, Jeroen Verhaeghe, Alan Miranda, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 24, 2022
Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [<sup>11</sup>C]CHDI-00485180-R and [<sup>11</sup>C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin
Aline Delva, Michel Koole, Kim Serdons, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 17, 2025
PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington's disease
Aline Delva, Michel Koole, Kim Serdons, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 13, 2020
The development of a structurally distinct series of BACE1 inhibitors via the (Z)-fluoro-olefin amide bioisosteric replacement
Michael Frohn, Longbin Liu, Aaron C Siegmund, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 17, 2023
In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease
Daniele Bertoglio, Alison R Weiss, William Liguore, et al.
Bioorganic & Medicinal Chemistry
|
April 18, 2016
Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling
Longbin Liu, Matthew R Lee, Joseph L Kim, et al.
Journal of Medicinal Chemistry
|
February 11, 2012
Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series
Longbin Liu, Mark H Norman, Matthew Lee, et al.
Journal of Medicinal Chemistry
|
April 28, 2015
Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis
Nuria A Tamayo, Mark H Norman, Michael D Bartberger, et al.
Page
of 6